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Abstract
Background: We designed a seroprevalence study using multiple testing assays and population sources to estimate the
community seroprevalence of pH1N1/09 and risk factors for infection before the outbreak was recognized and throughout
the pandemic to the end of 2009/10 influenza season.
Methods: Residual serum specimens from five time points (between 01/2009 and 05/2010) and samples from two time
points from a prospectively recruited cohort were included. The distribution of risk factors was explored in multivariate
adjusted analyses using logistic regression among the cohort. Antibody levels were measured by hemagglutination
inhibition (HAI) and microneutralization (MN) assays.
Results: Residual sera from 3375 patients and 1024 prospectively recruited cohort participants were analyzed. Pre-
pandemic seroprevalence ranged from 2%–12% across age groups. Overall seropositivity ranged from 10%–19% post-
first wave and 32%–41% by the end of the 2009/10 influenza season. Seroprevalence and risk factors differed between
MN and HAI assays, particularly in older age groups and between waves. Following the H1N1 vaccination program,
higher GMT were noted among vaccinated individuals. Overall, 20–30% of the population was estimated to be
infected.
Conclusions: Combining population sources of sera across five time points with prospectively collected epidemiological
information yielded a complete description of the evolution of pH1N1 infection.
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Introduction
In Canada, the first cases of pandemic H1N1 2009 (pH1N1/09)
were reported on April 26, 2009; two days later the first cases were
reported in the province of Ontario [1], the largest province in the
country. The number of reported cases in Ontario increased
rapidly, with the peak of the first wave occurring by mid–May then
tapering off in the summer months. The second wave began in the
fall of 2009 and peaked during the last week of October. Starting
October 26, 2009, Ontario began a mass pH1N1/09 vaccination
program initially focusing on priority groups and expanding to the
general population by November 16, 2009 [2]. By the end of
January 2010, 8791 lab confirmed cases and 1843 hospitalizations
associated with pH1N1/09 had been reported in Ontario [3].
Surveillance data based on laboratory confirmed cases capture
only a fraction of the true cases of influenza since not all infected
individuals are symptomatic, seek medical attention and provide
specimens for laboratory testing. The extent to which surveillance
reflects the true burden of disease was also affected by changes in
the laboratory testing recommendations. Given the limitations in
these data we designed a seroprevalence study with the following
objectives: to estimate the community seroprevalence of pH1N1/
09 in January 2009 before the outbreak was formally recognized;
to assess the extent of community transmission of pH1N1/09 at
multiple time points from January 2009 to the end of influenza
season in April/May 2010; to identify the risk factors for infection
with pH1N1/09, and; to assess the antibody response in
individuals that were vaccinated during the second wave. Our
aim was to develop an as complete as possible picture of the
evolution of seroprevalence over the whole course of the 2009
H1N1 pandemic in Ontario.
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Ethics Statement
The research protocol entitled ‘‘A Seroprevalence study of novel
swine influenza A H1N1 among Ontarians’’ (protocol reference
#24130) was granted approval by the Health Sciences Research
Ethics Board at the University of Toronto, Canada. Written
informed consent was obtained from participants.
Study Populations
We obtained specimens from two sources and three populations
at multiple time periods (table 1). Firstly, we recruited a
prospective cohort of Ontario residents and followed them up
after the first and second wave of pH1N1/09. Secondly, we
assembled a repository of residual serum specimens submitted to
Public Health Ontario Laboratories (PHOL) for preventable
disease and prenatal screening at five time points from January
2009 to April/May in 2010.
Prospective Cohort Study
We invited Ontario residents who were 18 years or older,
available for follow–up in August/September 2009, able to
communicate in English and answer an online questionnaire to
participate in the study. Participants provided informed consent
and completed a web-based questionnaire on health behaviours,
health history and demographic information. Blood specimens
were collected in serum separator tubes (SST tubes) at medical
laboratory locations throughout Ontario. We aimed to recruit
1800 participants (600 from each of 3 age groups: 18–29, 30–64
and 65 years of age and older) in order to have 80% power to
detect a difference in seroprevalence of 10%. We recruited
through news releases, news articles, newspaper advertisements,
emails to stakeholders, Google ad words and Facebook. Newspa-
per readership in the selected newspapers was over 1 million
individuals per day, and at the time, the term ‘‘H1N1 flu virus’’
demonstrated a high percentage of all Google searches. In April
2010, study participants who were seronegative by hemagglutina-
tion inhibition assay (HAI) assay after wave 1 were invited to
provide a second blood sample and complete another online
questionnaire on risk factors, health status and vaccination history.
Residual Specimens
In Ontario, all preventable disease and prenatal screening tests
are performed by OAHPP laboratories. These specimens are
submitted for a variety of reasons including occupational
screening, requiring proof of immunity for school purposes, and
screening of new immigrants. Prenatal screening is recommended
for all pregnant women in the province. Residual sera held by
OAHPP were randomly selected and had complete information
on sex, age, and residence (appendix S1).
Laboratory Testing
Sera were extracted from blood specimens and tested by HAI to
determine antibody titres against the pH1N1/09 influenza strain
(A/California/07/2009–like) and the 2008–2009 seasonal H1N1
influenza strain A/Brisbane/59/07 (Brisbane H1N1) to identify
potential cross-reactivity. The HAI and microneutralization (MN)
protocols were adapted from previously published World Health
Organization (WHO) methods [4]. Briefly, the HAI assay was
performed with 0.7% guinea pig erythrocytes and 4 HA units of
virus. For MN, a twofold serial dilution was completed on the sera
starting with 1:40 dilution. Diluted sera and 100TCID50
infectious units of virus were added in equal amounts to each
well in a U-shaped microtitre plate. The plates were incubated for
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bottomed microtitre plates containing confluent monolayer
Madin-Darby Canine Kidney (MDCK) cells (Diagnotic Hybrids
Inc., Ohio, USA) were washed with virus growth medium. The
virus-antibody mixture was added to the corresponding wells in
the microtitre plate containing MDCK cell monolayer and
incubated for a further 2 hours at 37uC. The contents were then
removed and replaced with virus growth medium. The plate was
then again incubated at 37uC and monitored for the appearance
of cytopathic effects on days 3, 4, and 5. The reciprocal of the
highest dilution of the antibody that inhibited the development of
viral CPE was designated as the titre. Screening of the samples was
done in triplicate wells and the titration was done in duplicate
wells. Samples with a titre of 1:40 or greater were considered
seropositive for both assays [5–9].
Statistical analysis
We calculated the proportion of seropositive participants for
each age group, time period and study population with 95%
confidence intervals according to the binomial distribution.
To assess the strength of the association between risk factors and
positive seroprevalence status in the cohort study, we calculated
unadjusted and age-adjusted odds ratios (OR) with 95%
confidence intervals using logistic regression analysis. Multivariate
logistic regression was fit to determine independent predictors and
variable selection done was completed using the Hosmer-
Lemeshow forward model building strategy. Briefly, univariate
logistic regression for each independent variable was conducted.
Variables that were significant using a cut-off of 0.2 were
considered as candidates in the multivariate model. Variables
were added based on level of importance using magnitude of the
odds ratio and a priori variables (age and sex). Variables were
retained in the final multivariate model if they were significant
(P,0.05) or determined a priori. Geometric mean titres (GMTs)
were calculated for cohort study participants who provided
samples post-wave 1 and at the end of the 2009/10 influenza
season. For titres lower than 10 (,1:10), GMTs were estimated by
assigning a value of 5. Sensitivity and specificity of the HAI was
calculated using the MN assay as gold standard. All analyses were
completed in SAS version 9.1.
Results
We collected residual serum specimens from 3375 individuals
who had submitted during our time periods of interest. For the
cohort study, 1486 people registered to take part in the study and
of those, 53 (3.6%) withdrew primarily due to difficulties
scheduling appointments to provide a blood specimen. Among
the remainder, 1245 (86.9%) completed the online questionnaire
and 1069 (74.6%) had a blood specimen collected. Forty-five
participants who provided blood specimens after October 5, 2009
were excluded, leaving 1024 or 68.9% for analysis post wave 1. In
April 2010, 941 seronegative individuals who were asked to
provide another specimen. Thirty-eight (4.0%) actively withdrew
and 518 (57.4%) did not respond leaving 385 in the cohort study
for the post-wave 2 analysis (appendix S2).
Compared with the general population, preventable disease
residual specimens were more likely to be female and living in the
Toronto region (table 2). Cohort study participants were more
likely to be female, white, born in Canada, university educated, a
health care worker and older than 65 years of age (table 2).
For each study population, pH1N1/09 seroprevalence levels
increased until after the second wave with the largest increases
occurring in the younger age groups. Overall pre-existing
seropositive levels ranged from 2.0 to 12.0%, with those 65 years
and older having the highest levels. Following wave 1, seroprev-
alence in study populations ranged from 10.9 to 18.3% overall
with the highest proportions seen in the prenatal residual samples
and generally among those in younger age groups. At the end of
the 2009/10 influenza season, overall seroprevalence levels ranged
from 32.2% to 40.9%, but varied greatly between age groups. In
the residual samples seropositivity dropped slightly between the
end of the second wave and the end of the influenza season
(January to May 2010) (table 3).
The MN assay indentified a larger number of infections
compared with HAI, particularly among those 65 years of age
and older (P,0.0001) (figure 1). The sensitivity of the HAI assay
compared to the MN assay as a gold standard increased
significantly from 53% (44%–60%) post-wave 1 to 82% (74%–
88%) at the end of the influenza season (data not shown). In the
cohort study, individuals 80 years and older had the highest
pH1N1/09 seroprevalence following wave 1 and at the end of the
2009/10 influenza season as measured by HAI; however,
confidence intervals were wide given the limited sample size
within this age strata.
Table 4 shows the age-adjusted OR among the cohort study
participants associated with each risk factor and pH1N1/09
seroprevalence following the first wave as measured by both HAI
and MN assays. Independent predictors of serological status by
HAI were: being a Toronto resident, experiencing fever and cough
since April 1
st 2009, receiving the 2008/09 influenza vaccine, and
attending a large family gathering. Seropositivity by MN was
significantly associated with reporting ‘flu-like symptoms’ or fever
and cough and receiving the 2008/09 influenza vaccine. The OR
for age showed younger individuals were less likely to be positive
by MN status but more likely to be positive using the HAI;
however, the confidence intervals overlapped. In the multivariate
analysis receiving the 2008–9 vaccine was only significant using
HAI (OR=1.68 95% C.I 1.04–2.70) and did not reach
significance using MN (OR=1.35 95% C.I 0.91–2.02). Associa-
tions with large family gatherings were significant in the
multivariate HAI analyses; however, no significant effects were
found with travel or hand hygiene.
Among the 385 seronegative individuals that were followed in
the cohort study, 270 received the pH1N1/09 vaccine (table 5).
Based on HAI results, among the 95 participants who did not
receive the vaccine, 13/95 (13.7%) were seropositive at the end of
the 2009/10 influenza season. Forty-nine percent of individuals
that received the vaccine were classified as seropositive; however,
GMTs were significantly higher among vaccinated participants.
Amongst the vaccinated, females (p=0.0213) and adults under 65
years of age (p=0.0066) were significantly more likely to remain
seropositive at follow up.
Using age-specific seropositivity rates as well as population
estimates in Ontario and baseline seroprevalence in the popula-
tion, the total outbreak size is estimated between 2.4 and 3.9
million, or 18–30% of the population, implying that routine
laboratory surveillance detected approximately 1 in 350 cases of
infection Ontario. It is estimated that the infection rate in the
second wave was 2.0–3.2 times the size of the first wave. (details
provided in appendix S3).
Discussion
Our results draw a near-complete picture of the evolution of
seropositivity to pandemic H1N1from before the onset to the end
of the 2009/10 influenza seasons in a large Canadian province,
using a variety of study populations and prospectively collected
Seroprevalence Study of pH1N1
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e26427Table 2. Demographic characteristics of each study population compared to the general population of Ontario.
Category Number and Proportion of Participants n (%)
Proportion of Ontario’s
Population, % [35–37]
Preventable Disease Residual
Specimens (N=2899)
Prenatal Residual
Specimens (N=476)
Cohort Study
(N=1024)
,18* 494 (17) 93 (20) - 24
18–29 years{ 480 (17) 127 (27) 160 (17) 14
30–64 years{ 1387 (48) 256 (54) 525 (56) 49
65+ years 538 (19) – 259 (27) 13
Female 2010 (69) 476 (100) 551 (58) 51
Male 887 (31) 0 (0) 392 (42) 49
Toronto 1128 (39) 249 (52) 232 (23) 21
Central East 820 (28) 154 (32) 227 (23) 29
Eastern 202 (7) 2 (,1) 207 (21) 13
Central West 486 (17) 55 (12) 175 (18) 19
South West 207 (7) 1 (,1) 115 (12) 12
North East 40 (1) 9 (2) 34 (3) 4
North West 10 (,1) 4 (1) 7 (1) 2
White – – 875 (93) 77
Non-white – – 70 (7) 23
University degree – – 553 (59) 20
No university degree – – 392 (41) 80
Health-care worker – – 138 (15) 5
Teacher (pre-school to grade 12) – – 42 (4) 4
Child care worker – – 5 (,1) 1
Other – – 750 (80) 90
*For prenatal residual specimens, only ages 10 to 17 years are included. For the Ontario population, includes those ,20 years of age.
{For the Ontario population, includes those 20–29 years of age.
{For prenatal residual specimens, only ages 30 to 49 years are included.
doi:10.1371/journal.pone.0026427.t002
Table 3. Proportion seropositive by HAI assay by age group, time period and study population.
Study population Time period % Seropositive (95%CI)
,18 yrs 18–29 yrs 30–64 yrs 65+ yrs Total
Cohort Study 3. Post-wave 1 pandemic 14.4 (8.9–19.8) 10.7 (8.0–13.3) 8.9 (5.4–12.3) 10.9 (9.0–12.8)
5. End of flu season (only
seronegatives from period 3)
45.2 (30.2–60.3) 43.7 (36.6–50.7) 33.3 (25.3–41.4) 40.0 (35.1–44.9)
,18 yrs 18–29 yrs 30–64 yrs 65+ yrs Total
Preventable disease
residual samples
1. Pre-pandemic 2.0 (0.0–5.8) 7.4 (0.4–14.4) 4.1 (1.3–6.9) 12.0 (5.0–19.1) 6.0 (3.6–8.4)
2. Early Wave 1 pandemic 3.7 (0.0–8.7) 7.4 (0.4–14.4) 8.1 (4.3–11.9) 15.6 (7.5–23.7) 8.9 (6.0–11.7)
3. Post-wave 1 pandemic 21.6 (13.0–30.2) 12.5 (5.6–19.4) 11.0 (7.1–14.9) 19.0 (10.7–27.4) 14.5 (11.4–17.5)
4. Post-wave 2 pandemic 63.8 (56.3–71.2) 38.8 (30.7–47.0) 36.8 (32.0–41.6) 35.9 (28.4–43.4) 42.1 (38.8–45.5)
5. End of flu season 61.7 (53.7–69.7) 37.9 (30.0–45.8) 36.3 (31.4–41.3) 34.8 (26.8–42.7) 40.9 (37.5–44.3)
,18 yrs 18–29 yrs 30–64 yrs 65+ yrs Total
1. Pre-pandemic n/a n/a n/a n/a n/a
Prenatal residual
samples
2. Early wave 1 pandemic 4.2 (0.0–12.2) 11.1 (0.0–23.0) 9.3 (1.5–17.0) n/a 8.6 (3.2–13.9)
3. Post-wave 1 pandemic 27.6 (11.3–43.9) 10.0 (0.0–20.7) 18.0 (8.4–27.7) n/a 18.3 (11.4–25.3)
4. Post-wave 2 pandemic 29.4 (14.1–44.7) 48.5 (31.4–65.5) 43.5 (31.6–56.0) n/a 41.2 (32.9–49.4)
5. End of flu season 83.3 (35.9–99.6) 32.4 (17.3–47.5) 27.8 (17.4–38.1) n/a 32.2 (23.6–40.7)
doi:10.1371/journal.pone.0026427.t003
Seroprevalence Study of pH1N1
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e26427Figure 1. pH1N1/09 seroprevalence levels stratified by age group and serological assay among cohort study participants post-
wave 1 (A) and among seronegative cohort study participants followed at the end of 2009/10 influenza season (B).
doi:10.1371/journal.pone.0026427.g001
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serological data indicate that approximately 24% of the population
were infected with pH1N1, which is higher than Hong Kong [10],
Australia [11] and New Zealand [12].
Our findings are consistent with laboratory surveillance such
that the highest rates of infection were noted in younger age
groups, particularly school-aged children [3,12–14]. Consistent
with other seroprevalence studies and a systematic review [15], we
observed a significant increase from baseline seroprevalence levels
among children; however no increase was observed in adults 60
years of age and older [12]. Several seroprevalence studies have
demonstrated higher levels of immunity in older age groups
[5,12,16–22]. The higher seroprevalence in the older age groups,
particularly those 80 years of age and older, likely represents cross-
reactivity due to pre-existing antibodies to previously circulating
influenza viruses as sequence comparisons have shown that the
hemagglutination gene of pH1N1/09 virus is closely related to
1918 and 1976 viruses [19].
Table 4. Analysis of risk factors associated with pH1N1/09 seroprevalence among cohort study participants post wave 1 in
August–September 2009.
Risk factor HAI assay Microneutralization assay
Age-adjusted
OR (95% CI)
Multivariate*
adjusted OR (95% CI)
Age-adjusted
OR (95% CI)
Multivariate*
adjusted OR (95% CI)
Male 0.91 (0.59–1.39) 0.93 (0.59–3.11) 1.02 (0.71–1.46) 1.11 (0.76–1.62)
Age group
18–29 n/a 1.55 (0.77–3.11) n/a 0.80 (0.45–1.43)
30–64 n/a 1.21 (0.70–2.11) n/a 0.65 (0.43–0.99)
65+ Reference Reference
Toronto resident 1.62 (1.03–2.53) 1.91 (1.18–3.10) 1.01 (0.66–1.54)
Non-white ethnicity 1.56 (0.79–3.10) 0.87 (0.41–1.83)
Canadian-born 0.76 (0.45–1.29) 0.77 (0.49–1.19)
Secondary level/technical education only 0.54 (0.27–1.06) 0.95 (0.59–1.54)
Experienced ‘flu-like symptoms’ since April 1, 2009 2.28 (1.45–3.57) 1.90 (1.31–2.77)
Experienced fever and cough since April 1, 2009 2.69 (1.69–4.29) 2.52 (1.54–4.06) 1.99 (1.30–3.05) 1.99 (1.29–3.07)
Received 08/09 Seasonal flu vaccine 1.81 (1.15–2.86) 1.68 (1.04–2.70) 1.48 (1.01–2.18)
Received 07/08 seasonal flu vaccine 1.67 (1.02–2.75) 1.17 (0.77–1.77)
Received 06/07 seasonal flu vaccine 1.48 (0.88–2.48) 1.01 (0.65–1.55)
Flu vaccine doses
Three 2.30 (1.20–4.42) 1.33 (0.79–2.23)
Two 1.53(0.71–3.29) 1.10 (0.59–2.06)
One 2.02 (0.88–4.63) 1.23 (0.59–2.57)
None Reference Reference
Previously tested for pH1N1/09 2.65 (0.95–7.38) 1.20 (0.40–3.61)
Chronic medical condition 1.29 (0.82–2.02) 1.35 (0.92–1.97)
Currently pregnant 1.37 (0.38–5.00) 0.36 (0.05–2.81)
Health care worker 1.33 (0.77–2.29) 0.79 (0.45–1.36)
Lives in a household of 4+ individuals 0.98 (0.59–1.61) 0.83 (0.52–1.33)
Lives with school-aged children 1.23 (0.75–2.02) 1.08 (0.68–1.72)
Visited a school or child care centre since April 1, 2009 1.14 (0.75–1.74) 1.23 (0.85–1.78)
Attended a large public gathering since April 1, 2009 0.85 (0.55–1.33) 0.63 (0.43–0.91)
Attended a large family gathering since April 1, 2009 1.60 (0.97–2.63) 1.76 (1.03–3.01) 0.97 (0.66–1.42)
Transit
Everyday 1.26 (0.65–2.46) 1.06 (0.57–1.95)
More than once a week 1.42 (0.77–2.62) 0.94 (0.52–1.70)
Once a week 0.82 (0.43–1.59) 0.69 (0.39–1.21)
Never Reference Reference
Hand washing
7 or more times/day 0.92 (0.37–2.28) 0.94 (0.42–2.08)
3 to 6 times/day 0.79 (0.32–1.97) 0.86 (0.39–1.94)
0 to 2 times/day Reference Reference
*Aside from age and sex all variables in multivariate model are significant at p,0.05.
doi:10.1371/journal.pone.0026427.t004
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prenatal screening populations were similar to two other smaller
seroprevalence studies conducted in Canada; however there were
important differences [5,23]. We observed differences in HAI
sensitivity compared to MN assay between the first and second
waves that were not found in the study from British Columbia [5].
We speculate that the apparent increased sensitivity of HAI in the
second wave is consistent with the hypothesis that antibodies
detected by MN peaks higher but wanes faster than HAI. The
differences may also be due to the fact that two assays target
different components of the virus hemagglutinin thus represent
different immunological markers. In addition, the risk factor
analysis differed between the assays, but this cannot be compared
with published seroprevalence studies in Canada that have not
included epidemiologic information. We did not observe any
association between seroprevalence and either public transit or
hand washing found in other settings [24,25]. This could be due to
the recall bias or error that may occur with the self-reporting of
this variable.
We estimated of the second wave to be approximately 2.6-fold
larger than the first, which is considerably lower than the reported
five-fold higher rate in hospitalizations in wave 2 versus wave 1 in
Canada [26]. As we measured all infections, compared to only
those that were symptomatic enough to warrant hospitalization,
this difference would be expected if either the average age at
infection or testing of hospitalized patients increased in wave 2.
Study participants who reported receiving seasonal influenza
vaccine in 2008/09 were significantly more likely to be
seropositive by HAI after adjusting for other factors. Cross-
reactivity of vaccine induced antibodies with pH1N1/09 antigen
in the HAI assay is an unlikely explanation because the effect size
was similar using MN, albeit non-significant. Previous studies have
shown increased pH1N1/09 antibody titres among adults who
received seasonal influenza vaccinations [20,21,27,28] and four
studies conducted in Canada have identified an association
between individuals who received the 2008/09 influenza vaccine
and becoming infected with medically attended pH1N1/09 [29].
Further examination of the affinity and origin of antibodies
detected in previously vaccinated individuals who acquired
pH1N1/09 is needed to better understand any potential biological
mechanisms.
Ontario distributed Arepanrix
TM H1N1 vaccine, an adjuvanted
influenza vaccine made by GlaxoSmithKline (GSK). Vaccine
coverage within our seronegative cohort study population was
70%, as compared to 33% reported in the general population
[30]. This discrepancy may be a result of prior knowledge of
susceptibility among participants. Among those who received the
pH1N1/09 vaccine, 49% were seropositive by HAI at the end of
the influenza season, approximately 6 to 8 months after the
vaccine was made available, although GMT levels were
significantly higher among the vaccinated group. This was lower
than expected from immunogenicity studies carried out by GSK
that demonstrated seroconversion rates of 92% and 80% at 42 day
follow-up also by HAI [31]. In our study, failure to have detectable
antibodies 6–8 months post-vaccination as defined by the 1:40 cut-
off as associated with increasing age, but it is unlikely the findings
can solely be explained by our study population being less healthy
or older, or by the longer time to follow up. HAI and MN are only
proxies for protective immunity; the clinical significance cannot be
explored by this methodology. Our findings support the decision
made to include the pandemic strain in the 2010/11 seasonal
vaccine and recommend it for those who had previously received
monovalent vaccine.
Several limitations should be considered when interpreting the
results of this study. The residual serum specimens were obtained
from predominantly female individuals who were more likely to
live in the Toronto region. Some of the selection biases in the
overall cohort are likely the result of our web-based methods for
recruitment and data collection. Individuals with limited computer
skills or access to the internet and individuals who were not fluent
in English would have been less likely to participate. The high
proportion of health care workers included in the cohort may be
due to an increased awareness of our relatively new organization
compared to the rest of the population. In addition, our blood
collection sites were primarily located in urban centres limiting
participants from rural and more isolated Northern communities.
Furthermore, we chose the cut-off of 1:40 for our assays in order to
ensure comparability with other studies; different cut-offs would
have altered our findings. In a study of the sensitivity and
specificity of pH1N1 tests, we found that HI may not be as
sensitive as MN even though HI is the commonly accepted
method for the detection of antibodies [32]. These differential test
performances have implications on the interpretation of serolog-
ical results for pH1N1. An international evidence-based consensus
on the use and interpretation of serology in relation to assessing
both immunity and as evidence of recent or past infection would
be helpful in this regard. In addition to investigating humoral
immunity, it is also of utmost importance to investigate cell-based
immunity to explore the cross-reactive memory T cell responses
especially considering that antibodies wane over time and some
individuals may not produce antibodies [33].
There are various approaches to serological testing in the
population, including active population recruitment and passive
testing of blood specimens, both of which have for potential
selection biases. The advantage of active recruitment is the ability
to collect epidemiological information, which can reveal bias and
determine risk factors and patterns of serostatus in the population
that is not possible through passive data collection. While the
Table 5. Number and proportion of seropositive participants by HAI and microneutralization and GMT pre and 6–8 months post-
vaccine measured by HAI assay among seronegative cohort study participants followed up at the end of the influenza season in
April–May 2010.
Vaccine Total
No. (%) pH1N1/09
seropositive HAI
No. (%) pH1N1/09 seropositive
Microneutralization
GMT pre-vaccine
(95% CI)
GMT 6–8 month post-vaccine
(95% CI)
Received pH1N1/09 vaccine No 95 13 (13.7) 10 (10.1) 8.5 (5.1–12.0) 10.8 (6.3–15.3)
Yes 270 133 (49.3) 120 (44.3) 8.3 (5.0–11.7) 30.1 (24.2–35.9)
Total* 385 154 (40.0) 134 (34.8) 8.4 (5.0–11.7) 23.4 (17.4–29.5)
*pH1N1/09 vaccine status was unknown for 20 participants.
doi:10.1371/journal.pone.0026427.t005
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preventable disease screening, cannot be measured, it may differ
from those actively recruited and may not be associated with the
outcome. We adopted multiple approaches in order to be more
representative of the population. We found synthesizing data from
both sources over time extremely useful to represent a more
complete picture of the pandemic. Methods to reduce selection
bias in serosurveys and the establishment of biorepositories are
important future considerations.
This study synthesizes a range of different sources of serological
data with prospectively collected epidemiologic information. The
collection of data across different time points allows us to observe
the evolution of the pandemic, both prior to and after the
vaccination program. The results of this seroprevalence study were
important because they allowed decision makers to use estimates
of susceptibility in the local population to plan resources and
support public health action, including vaccination programs,
during the second wave and the subsequent influenza season.
Before another infectious disease emerges it would be wise to
incorporate the need for seroprevalence studies into planning
processes and public health emergency plans, establish biorepo-
sitories of representative sera as well as the laboratory capacity to
test specimens quickly to answer such questions. This experience
using multiple assays and population sources will facilitate the
introduction of a provincial serosurvey in the event of widespread
outbreaks, a future pandemic or other public health emergency.
Results are currently being applied to the evaluation of the
pandemic response and for pandemic planning.
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